Insulin resistance is associated with elevated serum pigment epithelium-derived factor (PEDF) levels in morbidly obese patients

Acta Diabetologica

Volumn 49, Issue 1 SUPPL., 2012, Pages

  Gattu, Arijeet K ^a,b   Birkenfeld, Andreas L ^b   Jornayvaz, Francois ^b   Dziura, James ^b   Li, Fangyong ^b   Crawford, Susan E ^c   Chu, Xin ^d   Still, Christopher D ^d   Gerhard, Glenn S ^d   Chung, Chuhan ^a,b,e   Samuel, Varman ^a,b  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NorthShore Research Institute   (United States)

^d WEIS CENTER FOR RESEARCH   (United States)

^e Section of Digestive Diseases   (United States)

Author keywords

Gastric bypass; Insulin resistance; PEDF

Indexed keywords

GLUCOSE; INSULIN; PIGMENT EPITHELIUM DERIVED FACTOR; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ADIPOCYTE; ADULT; ARTICLE; BODY MASS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; HUMAN CELL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER CELL; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MORBID OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SCORING SYSTEM; STOMACH BYPASS; BLOOD; CELL CULTURE; METABOLISM; MIDDLE AGED;

ADIPOCYTES; ADULT; BLOOD GLUCOSE; CELLS, CULTURED; EYE PROTEINS; FEMALE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; OBESITY, MORBID; SERPINS;

EID: 84878893936     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-012-0397-y     Document Type: Article

References (39)

1. Kopelman PG (2000) Obesity as a medical problem. Nature 404(6778):635-643
2. Calle EE et al (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348(17):1625-1638
3. Oda E (2012) Metabolic syndrome: its history, mechanisms, and limitations. Acta Diabetol 49(2):89-95
4. Yamagishi S et al (2006) Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 91(6):2447-2450
5. Wang P et al (2008) Plasma pigment epithelium-derived factor is positively associated with obesity in Caucasian subjects, in particular with the visceral fat depot. Eur J Endocrinol 159(6):713-718
6. Sabater M et al (2010) Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab 95(10):4720-4728
7. Chen C et al (2010) Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: a 10-year prospective study. J Clin Endocrinol Metab 95(11):5074-5081
8. Nakamura K et al (2010) Serum levels of pigment epithelium-derived factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. Int J Cardiol 143(1):96-98
9. Jenkins A et al (2008) Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract 82(1):e5-e7
10. Jenkins AJ et al (2007) Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 24(12):1345-1351
11. Oberbach A et al (2011) Combined proteomic and metabolomic profiling of serum reveals association of the complement system with obesity and identifies novel markers of body fat mass changes. J Proteome Res 10(10):4769-4788
12. Yilmaz Y et al (2011) Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clin Chim Acta 412(23-24):2296-2299
13. Nakamura K et al (2009) Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 25(1):52-56
14. Galhardo J et al (2012) Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with acanthosis nigricans in obese adolescents. Diabet Med. doi: 10.1111/j.1464-5491.2012.03592.x
15. Tombran-Tink J, Chader GG, Johnson LV (1991) PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 53(3):411-414
16. Dawson DW et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245-248
17. Crowe S et al (2009) Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab 10(1):40-47
18. Kratchmarova I et al (2002) A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics 1(3):213-222
19. Zvonic S et al (2007) Secretome of primary cultures of human adipose-derived stem cells: modulation of serpins by adipogenesis. Mol Cell Proteomics 6(1):18-28
20. Cao Y (2007) Angiogenesis modulates adipogenesis and obesity. J Clin Invest 117(9):2362-2368
21. Wang M et al (2009) Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab 297(6):E1378-E1387
22. Chung C et al (2008) Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 48(3):471-478
23. Borg ML et al (2011) Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes 60(5):1458-1466
24. Yamagishi S et al (2006) Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 281(29):20213-20220
25. Yoshida T et al (2008) Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 40(9):620-625
26. Park JS et al (2010) Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients. Acta Diabetol 47(2):113-118
27. Yamagishi S et al (2004) Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 37(2):497-506
28. Chung C et al (2009) Ethanol exposure depletes hepatic pigment epithelium-derived factor, a novel lipid regulator. Gastroenterology 136(1):331-340 e2
29. Zeigerer A et al (2008) Insulin regulates leptin secretion from 3T3-L1 adipocytes by a PI 3 kinase independent mechanism. Exp Cell Res 314(11-12):2249-2256
30. Karra E, Chandarana K, Batterham RL (2009) The role of peptide YY in appetite regulation and obesity. J Physiol 587(Pt 1):19-25
31. Franck N et al (2011) Identification of adipocyte genes regulated by caloric intake. J Clin Endocrinol Metab 96(2):E413-E418
32. Tombran-Tink J et al (1996) Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis 2:11
33. Tahara N et al (2011) Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis 219(1):311-315
34. Tschoner A et al (2011) Effect of weight loss on serum pigment epithelium-derived factor levels. Eur J Clin Invest 41(9):937-942
35. Notari L et al (2006) Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 281(49):38022-38037
36. Romeo S et al (2008) Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 40(12):1461-1465
37. Rotman Y et al (2010) The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 52(3):894-903
38. Tian C et al (2010) Variant in PNPLA3 is associated with alcoholic liver disease. Nat Genet 42(1):21-23
39. Valenti L et al (2010) Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 51(4):1209-1217